Acronyms And Abbreviations |
|
xxi | |
Summary |
|
1 | (20) |
|
1 Introduction: The Imperative For Global Investment In Influenza Vaccines |
|
|
21 | (18) |
|
What If 2020 Had Been the "Year of Influenza" Instead? |
|
|
23 | (5) |
|
A Disruptive Moment to Reconsider Influenza in the Wider Pandemic Preparedness Landscape |
|
|
28 | (3) |
|
Charge to the Committee on Global Coordination, Partnerships, and Financing |
|
|
31 | (2) |
|
|
33 | (2) |
|
|
35 | (4) |
|
2 The Existing Global Governance Landscape For Influenza Vaccines |
|
|
39 | (20) |
|
World Health Organization and the Influenza "Regime Complex" |
|
|
39 | (1) |
|
Governance Gaps Exposed in the 2009 H1N1 "Swine Flu" Pandemic |
|
|
40 | (4) |
|
Expanding and Enhancing Influenza Surveillance Since 2009 |
|
|
44 | (3) |
|
A Snapshot of Current Influenza Vaccine Governance Structures and Frameworks |
|
|
47 | (5) |
|
The Global Influenza Strategy and the Governance Path Forward |
|
|
52 | (3) |
|
Key Findings and Conclusions |
|
|
55 | (1) |
|
|
56 | (3) |
|
3 Pathogen Sharing For Influenza Vaccine Production |
|
|
59 | (20) |
|
The Essential Need for Pathogen Sharing |
|
|
59 | (2) |
|
The Critical Importance of Access and Benefit Sharing |
|
|
61 | (1) |
|
|
62 | (1) |
|
Existing International Instruments for ABS |
|
|
63 | (5) |
|
Barriers and Gaps That Affect ABS for Influenza |
|
|
68 | (3) |
|
How Has the "COVID-19 Lens" Changed the Way Governments, Organizations, and Institutions Look at ABS Instruments? |
|
|
71 | (3) |
|
Key Findings and Conclusions |
|
|
74 | (1) |
|
|
75 | (4) |
|
4 Technology And Manufacturing Partnerships |
|
|
79 | (36) |
|
Platform Technologies in the COVID-19 Era |
|
|
79 | (4) |
|
New Industry Partnerships During COVID-19 |
|
|
83 | (1) |
|
The Current State of Influenza Vaccine Manufacturing and the Limitations of Egg-Based Vaccines |
|
|
83 | (2) |
|
New Technologies for Influenza on the Horizon |
|
|
85 | (2) |
|
Accelerating the Development of Platform Technologies for Influenza |
|
|
87 | (4) |
|
Geographically Distributed and Regional Manufacturing Models ("Hubs") |
|
|
91 | (2) |
|
Capabilities Required for the Transition to Platform Technologies |
|
|
93 | (1) |
|
Barriers and Pathways to Success for Effective Global Partnerships to Support Next-Generation Influenza Vaccines |
|
|
94 | (14) |
|
Key Findings and Conclusions |
|
|
108 | (2) |
|
|
110 | (5) |
|
5 Influenza Vaccine Access And Financing |
|
|
115 | (40) |
|
The CO VAX Facility and Its Shortfalls |
|
|
115 | (4) |
|
Approaching Equity in Vaccine Access for Influenza |
|
|
119 | (1) |
|
Lessons from the COVID-19 Vaccine Experience |
|
|
120 | (1) |
|
How Has Pandemic Financing Changed During COVID-19?: Funding for COVID-19 Preparedness and Response |
|
|
121 | (6) |
|
Financing PPR: Economic Principles |
|
|
127 | (3) |
|
IPPPR's Argument About PPR Financing |
|
|
130 | (1) |
|
Scale of Investment Needed to Improve Global PPR |
|
|
130 | (3) |
|
Strategies to Drive Investment in Influenza Preparedness and Response: Engaging High- and Middle-Income Countries |
|
|
133 | (1) |
|
Key Considerations in Determining Scale and Incentives for Financing PPR |
|
|
134 | (15) |
|
Key Findings and Conclusions |
|
|
149 | (2) |
|
|
151 | (4) |
|
6 Recommendations And The Path Forward |
|
|
155 | (36) |
|
Situating Influenza in the Broader Pandemic Preparedness and Response Context |
|
|
155 | (4) |
|
Conclusions and Recommendations |
|
|
159 | (24) |
|
|
183 | (5) |
|
|
188 | (3) |
|
|
|
A Committee And Staff Biographies |
|
|
191 | (12) |
|
B Committee Meeting Agendas |
|
|
203 | |